Duloxetine Fails to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients
Key Insights
The Alliance A221805 trial found that duloxetine, an antidepressant commonly used to treat chronic pain, does not prevent nerve damage caused by oxaliplatin chemotherapy in colorectal cancer (search) patients.
The randomized, double-blind, placebo-controlled trial enrolled 199 patients across 73 cancer centers and tested two duloxetine doses (30mg and 60mg daily) against placebo for 17 weeks.
Response rates were similar across all groups (65.2% for 30mg duloxetine, 66% for 60mg duloxetine, and 68% for placebo), showing no statistically or clinically meaningful difference.
A large randomized trial has demonstrated that duloxetine, a medication widely used to treat chronic pain and psychiatric conditions, does not prevent peripheral neuropathy (search) caused by oxaliplatin chemotherapy in patients with colorectal cancer (search). The findings from the Alliance A221805 trial, published in JCO Oncology Advances, represent the largest study to date specifically designed to evaluate duloxetine's preventive potential against oxaliplatin-induced nerve damage.
Study Design and Methodology
The double-blind, placebo-controlled, multicenter phase II trial enrolled 199 adults with stage II or III colorectal cancer (search) across 73 cancer centers throughout the United States. Led by Dr. Ellen M. Lavoie Smith, Interim Associate Dean of Research and Scholarship at the University of Alabama at Birmingham School of Nursing, the study randomly assigned participants to receive either duloxetine 30mg daily, duloxetine 60mg daily, or placebo.
All participants had no pre-existing neuropathy at baseline and received oxaliplatin chemotherapy at either 85 mg/m² every 2 weeks (6 or 12 doses) or 130 mg/m² every 3 weeks (4 doses). Treatment with duloxetine or placebo began on the first day of oxaliplatin-based chemotherapy and continued for 17 weeks.
The primary endpoint was a composite response measuring onset and symptom severity of sensory oxaliplatin-induced peripheral neuropathy (search), assessed in weeks 19 to 21 using patient-reported surveys focused on extremity numbness, tingling, and pain.
Clinical Outcomes
Of the 199 enrolled patients, only 143 were evaluable for the primary endpoint analysis due to modified intention-to-treat criteria. Adherence rates fell below 75% across all study arms, highlighting challenges in maintaining consistent dosing throughout the treatment period.
The trial failed to meet its primary endpoint, showing no statistically or clinically meaningful difference between treatment arms. Response rates were remarkably similar across groups: 65.2% of evaluable patients in the 30mg duloxetine arm (n=46), 66% in the 60mg duloxetine arm, and 68% in the placebo arm achieved the composite endpoint of having a highest sensory oxaliplatin-induced peripheral neuropathy (search) score of two or less without withdrawing from the study due to neuropathy.
Approximately 27% to 30% of patients in each arm developed sensory oxaliplatin-induced peripheral neuropathy (search) scores above two, indicating more severe nerve damage regardless of treatment assignment.
Safety Profile
Grade 3 or higher adverse events occurred in 30.2% of patients receiving 30mg duloxetine, 36.1% receiving 60mg duloxetine, and 31.3% receiving placebo. Diarrhea was the most commonly reported grade 3 or higher adverse event across all treatment groups.
Two participant deaths occurred during the study, with only one considered possibly treatment-related: grade 4 hypokalemia in a patient receiving 60mg duloxetine.
Clinical Implications
"Since we know duloxetine is effective at treating painful neuropathy caused by neurotoxic chemotherapy drugs, we wanted to see if the medication could also prevent the side effect from developing in the first place," explained Dr. Smith. "The results show that duloxetine is not more effective than a placebo at preventing neuropathy caused by chemotherapy in patients with colorectal cancer (search)."
The findings have important implications for clinical practice. Oxaliplatin remains a standard chemotherapy drug for treating colorectal cancer (search), but peripheral neuropathy (search) represents a significant side effect that can cause permanent numbness, tingling, and pain in the hands and feet, substantially affecting long-term quality of life for cancer survivors.
"While duloxetine remains an important option for managing painful chemotherapy-induced neuropathy once it develops, this trial confirms that it should not be used for prevention," Dr. Smith emphasized.
Unmet Medical Need
The negative results highlight the ongoing challenge in preventing chemotherapy-induced nerve damage. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is already recommended for treating established painful chemotherapy-induced peripheral neuropathy (search) and is commonly prescribed for conditions such as osteoarthritis, diabetic neuropathy, anxiety, and depression.
The findings underscore the continued need for effective preventive strategies against chemotherapy-induced peripheral neuropathy (search), which remains a significant limitation in cancer treatment that can force dose reductions or treatment discontinuation.
This research was supported by the National Cancer Institute of the National Institutes of Health under awards UG1CA189823, UG1CA189972, R01CA235726, and U10CA180868, reflecting the importance of addressing this critical unmet need in oncology care.